NGHIÊN CỨU TÌNH HÌNH ĐỀ KHÁNG KHÁNG SINH CỦA NHÓM VI KHUẨN ESKAPE VÀ CHI PHÍ LIÊN QUAN TẠI BỆNH VIỆN BỆNH NHIỆT ĐỚI GIAI ĐOẠN 2020-2021

Abstract

Introduction: Antibiotic resistance is a global issue with increasing economic and health burdens. This study aims to analyze the characteristics and compare the treatment costs of patients with antibiotic-resistant and non-resistant infections caused by ESKAPE pathogens. Materials and Methodology: A retrospective study was conducted to assess the economic burden of ESKAPE bacteria from January 2020 to October 2021 at the Hospital for Tropical Diseases in Ho Chi Minh City. Results and discussions: Among 2,130 isolates, 1,176 cases were resistant (accounting for 55.23%) and 954 cases were sensitive (accounting for 44.77%). E. coli had the highest prevalence (31.22%), S. aureus (20.19%), K. pneumoniae (20.09%), P. aeruginosa (14.51%), and A. baumannii had the lowest prevalence (13.99%). The study found a higher proportion of resistant cases in patients with A. baumannii, E. coli, K. pneumoniae and S. aureus. In all bacterial groups, resistant cases were associated with higher median age, longer hospital stays, higher mortality rates, and significantly higher treatment costs compared to sensitive cases. The highest mortality rate was observed in patients infected with A. baumannii, while the lowest was seen in E. coli cases. Resistant P. aeruginosa had the highest average total treatment cost (339 million VND), while resistant E. coli had the lowest total cost (49 million VND). Drug costs, particularly antibiotics, represented the largest proportion of treatment expenses across all bacterial groups. Most patients were not covered by health insurance, except for those infected with E. coli, where most of the patients had 80%insurance coverage. Conclusion: Antibiotic resistance is a serious problem, with the proportion of resistant patients increasing and treatment costs rising over time, emphasizing the importance of controlling antibiotic resistance and optimizing treatment costs.